DTaP and Tdap vaccine side effects by brand (Infanrix, Daptacel, Boostrix, Adacel): VAERS data, trials and schedule
Side-effect reports for the Tdap vaccine from sourced pharmacovigilance data — VAERS and international AE databases by reaction category. Counts are database reports, not proven vaccine-caused injury rates.
How to read database counts: Pharmacovigilance systems (VAERS, EudraVigilance, Yellow Card, VigiBase, Lareb, DAEN) collect spontaneous, unverified reports. A report is not a confirmed adverse event and does not prove the vaccine caused the outcome. Under-reporting, stimulated reporting, and missing denominators limit rate interpretation. Compare with trials and epidemiological studies on each page before drawing conclusions.
Gold Standard EO (Aug 10, 2026)Federal recommendation status: Recommended for all children
The August 10, 2026 Executive Order on Gold Standard Childhood Vaccine Recommendations places diphtheria, tetanus, and pertussis (DTaP) in the Recommended for all children category. The EO also expresses a preference, to the maximum extent feasible, for administering all childhood immunizations at separate medical visits.
This page summarizes published pre-licensure clinical trial data, post-licensure surveillance findings, and peer-reviewed epidemiological studies for diphtheria, tetanus, and pertussis vaccines currently licensed in the United States (DTaP: Daptacel®, Infanrix®, and combination vaccines Kinrix®, Quadracel®, Pediarix®, VAXELIS®, Pentacel®; Tdap: Adacel®, Boostrix®). Safety and efficacy data are presented without interpretive language that implies the vaccine is "safe" or "unsafe." Data are drawn from FDA review documents, published clinical trials, VSD analyses, VAERS summaries, IOM/National Academies reports, and peer-reviewed literature.
Evidence state
For each outcome: the specific question, what controlled studies found, and how certain that evidence is on the GRADE scale (high, moderate, low, very low). Ratings are editorial judgments by the site applying GRADE to the studies in the table below — observational evidence starts at low and is rated up for large, consistent effects or a dose/age gradient, and down for inconsistency or imprecision (Methods). Where an effect is confined to a subgroup (for example young males), the question says so. "Not searched" means no controlled study has been compiled here yet; it is not a finding that the outcome is rare or caused by the vaccine.
Outcome & question
Finding & certainty
Why this rating
Febrile seizure
DTaP (acellular) vs whole-cell DTP (no longer used in the US)
no increase detected with DTaP; increased with whole-cell DTP Low (DTaP) certaintyModerate (whole-cell DTP) certainty
DTaP: one large risk-interval study. Whole-cell DTP: start low; +2 very large effect (RR 5.7) in a large VSD cohort. Studies: Huang 2010, Barlow 2001.See table
Pregnancy outcomes
Tdap during pregnancy
no increase in preterm birth, small-for-gestational-age, hypertensive disorders or neonatal sepsis; a small rise in coded chorioamnionitis in early studies was not confirmed later Low certainty
Large VSD cohorts with precise nulls for birth outcomes; chorioamnionitis inconsistent (RR 1.19–1.23 coded diagnosis vs HR 0.96 in a later cohort). Studies: Kharbanda 2014, DeSilva 2017, Greenberg 2023.See table
Guillain-Barré syndrome
Td
no increased risk detected Very low certainty
Single case-centered study with a wide interval. Studies: Baxter 2013.See table
Type 1 diabetes
Pertussis-containing vaccines
no increased risk detected Low certainty
Case-control study; IOM 2011 favours rejection. Studies: DeStefano 2001, IOM 2011.See table
Anaphylaxis
Not searched
No controlled-study result is compiled for this outcome yet.
Myocarditis or pericarditis
Not searched
No controlled-study result is compiled for this outcome yet.
Immune thrombocytopenia
Not searched
No controlled-study result is compiled for this outcome yet.
1. Basic Information
Diseases Protected Against
Diphtheria: Toxin-mediated bacterial infection (Corynebacterium diphtheriae) causing a pseudomembrane in the throat and airway obstruction; toxin can cause myocarditis and peripheral neuropathy. Case-fatality ~5–10%, higher in young children. Rare in the U.S. due to vaccination (~0–5 cases/year).
Tetanus (Lockjaw): Toxin-mediated infection (Clostridium tetani) from wound contamination. Causes painful muscle rigidity and spasms; can cause respiratory failure. Case-fatality ~10–20%. Universal; not contagious, so herd immunity does not apply. ~30 cases/year in U.S.; nearly all in unvaccinated or under-vaccinated persons.
Pertussis (Whooping Cough): Bacterial respiratory infection (Bordetella pertussis) causing paroxysmal cough, post-tussive emesis, and apnea in infants. Highest mortality in infants <3 months. Cyclical outbreaks every 3–5 years. The switch from whole-cell (DTwP) to acellular (DTaP) vaccine in the 1990s reduced reactogenicity but may have resulted in less durable immunity.
CDC Recommended Schedule (United States, 2025)
Dose/Age
Product
Notes
2 months
DTaP
Minimum age 6 weeks
4 months
DTaP
6 months
DTaP
15–18 months
DTaP
4th dose; minimum 6 months after dose 3
4–6 years
DTaP
5th dose; not needed if 4th dose given at ≥4 years
11–12 years
Tdap
Single booster; can be given at ≥7 years
Pregnancy (27–36 weeks)
Tdap
Every pregnancy, regardless of prior Tdap history; primarily to protect newborn from pertussis via maternal antibody transfer
Every 10 years (adults)
Td or Tdap
Decennial booster; one Tdap replaces one Td booster
Structured composition for 2 branded products covered on this page,
taken from FDA-approved package inserts (DailyMed / manufacturer prescribing information).
Lists are per product — formulations differ by manufacturer and presentation.
Click an ingredient name to open its safety-context page when available.
Ingredient lists are sourced from official package inserts for the specific brands named above.
Formulations can change between lots and over time — verify against the current label before any clinical decision.
Presence of a substance does not by itself indicate harm; toxicology is dose-, route-, and context-dependent.
Browse the full ingredient database:
Vaccine Ingredients index.
Causality assessment & potential mechanisms
Conditions below combine WHO-style causality levels with potential biological mechanisms
from the site mechanism catalog
(ae_mechanisms_catalog.json).
HRSA VICP table listing (where shown) indicates a compensable temporal association under U.S. program rules —
not automatic proof of causation for every case. Mechanisms are hypothesis-level pathways with graded evidence.
Pre-existing or newly formed IgE against vaccine antigens or excipients (e.g., gelatin, egg proteins, PEG, polysorbate) triggers mast-cell and basophil degranulation with systemic mediator release.
Vaccine- or infection-triggered immune responses cross-react with peripheral-nerve gangliosides or myelin components, producing demyelinating or axonal polyneuropathy.
Immune-mediated inflammation of brachial plexus nerves after antigenic stimulation (classically tetanus toxoid-containing vaccines), producing severe shoulder/arm pain and weakness.
Syncope (Fainting)HRSA table
0–1 days
Possible
Evidence: Moderate
Vasovagal (needle) syncope (primary · vasovagal)
Pain, anxiety, or orthostatic stress from injection triggers parasympathetic surge with bradycardia and hypotension, producing transient loss of consciousness—common in adolescents.
SIRVAHRSA table
0–2 days
Very likely / Probable
Evidence: High
SIRVA — incorrect injection into shoulder structures (primary · procedural)
Needle placement into the subdeltoid/subacromial bursa or joint rather than deltoid muscle causes prolonged local inflammation and restricted range of motion (procedural, not antigen-specific).
Extensive limb swelling (booster doses)
0–7 days
Possible
Evidence: Moderate
Adjuvant-driven local and systemic reactogenicity (primary · innate_inflammation)
Aluminum or other adjuvants (e.g., AS01B) amplify innate immune signaling, producing injection-site inflammation and transient systemic symptoms (fever, myalgia, fatigue).
Framework: WHO causality + HRSA VICP (where applicable) + AE mechanism catalog.
Last updated: 2026-07-18.
Schema: schemas/vaccine_injury_table.schema.json
· Mechanisms: schemas/ae_mechanism.schema.json.
Not medical or legal advice.
2. Pre-Licensure Clinical Trial Data
Licensure trial design (ICAN / OpenVAERS)
The table below reproduces ICAN’s No Placebo Table rows for U.S. childhood-schedule products relevant to this page — including the control/comparator used in FDA licensing trials (not always saline placebo). OSMF presents this for transparency; it is not an endorsement of ICAN interpretations.
Vaccine
Brand
Manufacturer
Doses (schedule)
Ages injected
Control / comparator
Placebo
Safety review window
DTaP
Infanrix
GSK
15
2M 4M 6M 15M 4Y
DTP
No
30 days
DTaP
Daptacel
Sanofi
15
2M 4M 6M 15M 4Y
DT or DTP
No
Up to 2 months + 1 trial 6 months
Tdap
Adacel
Sanofi
3
11Y
Td, for adults
No
6 months
Tdap
Boostrix
GSK
3
11Y
Decavac or Adacel
No
6 months
Source: OpenVAERS — No Placebo Table · ICAN original PDF
· Attribution: Informed Consent Action Network (ICAN) via OpenVAERS
· Last fetched: 2026-07-16.
For many trials listing '6 months' safety review, ICAN notes review was typically ~30 days post-injection with a phone call at 6 months.
Historical Context: DTwP to DTaP Transition
Whole-cell pertussis (DTwP) vaccines were introduced in the 1940s and were highly effective but reactogenic—commonly causing high fever, prolonged crying, and febrile seizures. Safety concerns (including a hypothesized association with encephalopathy, later not confirmed) led to the development of acellular pertussis (DTaP) vaccines, licensed in the U.S. between 1991 (first DTaP) and 2002 (Daptacel). The U.S. switched from DTwP to DTaP for all doses by 2002.
DTaP Pre-Licensure Trials (Daptacel / Infanrix)
The pivotal DTaP trials enrolled several thousand infants each. Daptacel (trial P3T06) included ~4,983 infants who received Daptacel vs. ~1,651 who received DTwP. Infanrix trials were multinational and similarly sized.
Adacel was evaluated in ~4,500 adolescents/adults. Boostrix in ~4,100. Both compared to Td (tetanus-diphtheria) vaccine. Primary endpoint was immunogenicity non-inferiority to the adult Td with demonstration of pertussis antibody responses.
Most Common Adverse Reactions
Reaction
DTaP (infants)
Tdap (adolescents/adults)
Injection site pain
~25–40%
~60–75%
Injection site swelling
~15–25%
~20–30%
Fever ≥38°C
~15–30% (lower than DTwP ~40–60%)
~3–8%
Irritability/fussiness
~30–55%
N/A
Drowsiness/decreased activity
~30–45%
N/A
Headache
N/A
~20–30%
Fatigue
N/A
~20–30%
Sources: Respective prescribing information; FDA review documents. Rates vary by study, product, and dose number.
Key Limitations
No placebo control: Modern DTaP trials used DTwP or other DTaP products as comparators, not placebo. This is ethically appropriate but limits the ability to detect absolute adverse event rates attributable to vaccination.
Waning immunity: Pre-licensure trials demonstrated initial efficacy but were not designed to assess durability. Post-licensure data have revealed substantially shorter duration of protection from acellular pertussis vaccines compared to whole-cell vaccines.
Combination vaccine complexity: Safety signals in combination vaccines (DTaP-IPV-Hib-HepB) are difficult to attribute to individual antigens.
Tdap in pregnancy: Initial licensure did not include safety data in pregnancy; the recommendation for every-pregnancy Tdap is supported by post-licensure observational data, not pre-licensure RCTs.
3. Post-Licensure Safety Data
Vaccine Safety Datalink (VSD)
The VSD has conducted extensive surveillance on DTaP/Tdap vaccines. Key findings:
Febrile seizures: DTaP is associated with a small increased risk of febrile seizures in the 0–1 day window post-vaccination in infants, particularly with concomitant PCV and influenza vaccines. Risk is ~1 per 15,000–25,000 doses.
Extensive limb swelling (ELS): With DTaP, ELS (involving ≥2/3 of the upper arm) is reported in ~2–6% of children after the 4th and 5th booster doses. Self-limited; not a contraindication to subsequent doses.
Tdap in pregnancy: Multiple VSD studies have found no increased risk of adverse pregnancy outcomes (preterm birth, low birth weight, congenital anomalies) or maternal adverse events associated with Tdap during pregnancy. A VSD study (Kharbanda et al., 2014; N>29,000 pregnancies) found no association with adverse birth outcomes.
Guillain-Barré Syndrome (GBS): No consistent signal with DTaP. For Tdap, VSD rapid cycle analysis found no significantly elevated GBS risk, though tetanus toxoid-containing vaccines have been hypothesized to have a very small association in some studies (see Section 4).
VAERS
VAERS Metric (DTaP/Tdap, cumulative)
Approximate Figures
Total DTaP doses distributed (estimated)
>1 billion doses globally since the 1990s
Most commonly reported AEs
Injection site reactions, fever, irritability (infants); injection site pain, headache, fatigue (Tdap in adolescents/adults)
Notable signal
Hypotonic-hyporesponsive episodes (HHE) in infants—resolved and well-characterized as rare, self-limited events associated primarily with DTwP; far less common with DTaP (~1–2 per 100,000 doses)
⚠ Critical Caveat
VAERS data represent unverified reports temporally associated with vaccination. A report to VAERS does not mean the vaccine caused the event. VAERS cannot be used to calculate incidence rates or establish causality.
Major Independent Reviews
Review
Year
Key Findings
IOM — "Adverse Effects of Vaccines"
2012
Favors acceptance of causal relationship for anaphylaxis and shoulder injury related to vaccine administration (SIRVA). Favors rejection for type 1 diabetes, autism, and SIDS. Evidence inadequate for GBS and chronic urticaria.
IOM — "DTaP and SIDS"
2003
Rejects causal association between DTaP and SIDS. Multiple large studies consistently find no association.
NASEM — Vaccine Safety Review
2020
No evidence the recommended schedule (including DTaP/Tdap) is associated with adverse neurodevelopmental outcomes.
VAERS reports per million doses
U.S. VAERS reports for vaccinations given 2006–2024, divided by the 879 million doses distributed in the same years (HRSA, from CDC data).
All reports
132
per million doses (131–132) · 115,599 reports
Serious reports
11.2
per million doses · 9,880 reports (death, life-threatening, hospitalised or disabled)
Reports with a death
1.31
per million doses · 1,150 reports
These are reporting rates: they mix real reactions, coincidental events and reports of conditions that would have happened anyway, and they depend on how actively each vaccine is watched. Doses are distributed, not administered. Combination vaccines count toward each component in both numerator and denominator. Compare with the observed-vs-expected analysis and the controlled studies above. Data: vaers_reporting_rates.json.
All vaccines, per million doses
Vaccine
All
Serious
Death
pcv
266
28.1
3.23
rotavirus
157
27.9
4.08
hpv
335
25.3
2.00
hib
126
19.7
3.25
polio
152
17.6
2.77
mmr
320
15.3
0.94
varicella
372
14.1
0.84
hepatitis-b
110
12.7
2.15
meningococcal
214
11.8
0.70
dtap
132
11.2
1.31
hepatitis-a
152
8.5
0.58
influenza
68
5.4
0.48
What controlled safety studies found
Unlike VAERS counts, these studies compare vaccinated people with a control group or control time window, so they can estimate whether a risk is raised and by how much. 14 results for DTaP/Tdap vaccines: 4 found an increased risk of a specific outcome, 9 found no increased risk.
Outcome
Design & population
Estimate (95% CI)
Excess per million doses
Finding
Source
Chorioamnionitis
Tdap in pregnancy
retrospective cohort (VSD, 7 sites) Pregnancies, US 2010-2013 (197,564)
Institute of Medicine (Stratton K et al., eds.), 2011, Adverse Effects of Vaccines: Evidence and Causality, National Academies Press doi:10.17226/13164
Benefit and risk on the same scale (per million)
Bars are drawn to scale within each comparison. Disease risks are per case of the disease; vaccine risks are the excess above background per dose, from controlled studies. How likely someone is to catch the disease, without vaccination, decides how these weigh up for an individual.
No single study measured both risks in the same population for this vaccine, so no side-by-side ratio is shown; the two lists below come from different studies, eras and populations.
Serious outcomes of the disease (per million cases)
Pertussis: Hospitalization; pneumonia; seizures
630,000
Infants <6 months with reported pertussis, US 1997-2000 · source
Pertussis: Hospitalization (DERIVED from annual means)
379,000
US infants (<1 year) with reported pertussis, 2000-2017 · source
Pertussis: Hospitalization
330,000
Infants <12 months with pertussis (current CDC page; no era stated) · source
Diphtheria: Death, unvaccinated without proper treatment
300,000
Unvaccinated individuals without adequate treatment · source
Days from vaccination to onset in U.S. VAERS reports (0–180 days). A causal reaction usually starts inside a characteristic window; but people also report what happens soon after a shot, so each event is compared with all other reports for this vaccine. The Weibull shape measures bunching (below 1 = most onsets early).
Event
Reports
Median days
In risk window
Shape (95% CI) vs others
Reading
Seizure (any)
8,931*
1
96% (others 98%)
0.71 (0.70–0.73) vs 0.74
same timing as other reports
Syncope
4,374
0
96% (others 76%)
0.81 (0.77–0.86) vs 0.74
spread later than other reports
Febrile seizure
1,956
1
97% (others 98%)
0.77 (0.74–0.82) vs 0.74
same timing as other reports
Intussusception
1,081
9
62% (others 53%)
0.84 (0.81–0.88) vs 0.74
spread later than other reports
Sudden infant death
924
3
75% (others 94%)
0.81 (0.77–0.86) vs 0.74
spread later than other reports
Anaphylaxis
454
0
94% (others 76%)
0.70 (0.63–0.80) vs 0.74
same timing as other reports
Guillain-Barré syndrome
405
13
85% (others 54%)
1.00 (0.92–1.06) vs 0.74
spread later than other reports
Herpes zoster
251
5
73% (others 54%)
0.60 (0.56–0.65) vs 0.74
clusters earlier than other reports
ADEM / encephalitis
240
5
81% (others 54%)
0.81 (0.75–0.93) vs 0.74
same timing as other reports
Bell's palsy / facial paralysis
142
2
77% (others 54%)
0.71 (0.64–0.81) vs 0.74
same timing as other reports
Immune thrombocytopenia
130
12
91% (others 54%)
1.00 (0.87–1.19) vs 0.74
spread later than other reports
Transverse myelitis
116
12
78% (others 54%)
0.92 (0.82–1.06) vs 0.74
spread later than other reports
Timing alone cannot establish causation; it can make it more or less plausible. *Fitted on a random sample of 5,000 of these reports. Data: vaers_onset.json.
VAERS Reporting Data — Halma & Varon (2025), DARE-SAFE
The DARE-SAFE paper (Halma & Varon, Pharmacoepidemiology 2025, CC BY 4.0) analyzed VAERS reports for vaccines administered in the United States from 2006–2022. The following data are extracted from Table 1 of that paper for this vaccine (DTaP only (excludes combination vaccines like DTaP-HepB-IPV, DTaP-IPV-Hib, etc.)):
Metric
Value
U.S. doses administered (2006–2022)
122,237,653
Total VAERS AE reports
25,629
AE reporting rate (per 100,000 doses)
21.0
Total death reports
656
Death reporting rate (per 100,000 doses)
0.537
AE-to-Death ratio
39:1
Source: Halma, M.; Varon, J. DARE-SAFE. Pharmacoepidemiology. 2025. DOI: 10.3390/pharma4020007. CC BY 4.0. Data from Table 1.
📚 Important Interpretive Caveats (from the paper itself)
Reporting rate ≠ incidence rate. VAERS is a passive, unverified system. A report means someone submitted a claim of temporal association, not a confirmed causal event. The paper is explicit that causality cannot be inferred from these numbers alone.
Reporting behavior is not uniform. More serious, unusual, or media-salient events are reported at much higher rates than mild ones. Products receiving more public, media, legal, and clinical attention (particularly COVID-19 vaccines, which also benefited from V-safe active-surveillance prompts and CICP compensation pathways) generate more reports per dose regardless of true risk.
Age and comorbidity confounding is not adjusted. COVID-19 vaccines were disproportionately administered to elderly and comorbid populations (nursing homes, 65+, high-risk groups in early 2021) with much higher background all-cause mortality than the general child/working-age population. Some fraction of temporally-associated deaths would occur regardless of vaccination, and the paper does not perform a background-rate comparison.
Stimulated reporting is a known, documented phenomenon. Media coverage, plaintiff attorney solicitation, and advocacy campaigns — all independently inflate VAERS reporting propensity. The paper cites this literature but does not correct for it.
Small-denominator rows are unreliable. Rates computed from small denominators (e.g., monovalent measles, DT, mumps, rubella) have enormous statistical uncertainty and should not be compared to vaccines with hundreds of millions of administered doses without noting the wide confidence intervals.
Source: Halma, M.; Varon, J. DARE-SAFE: Denominator-Adjusted Rate Estimates of Substance Adverse Events Frequency Evaluation in Pharmaceuticals and Vaccines. Pharmacoepidemiology. 2025, 4, 7. DOI: 10.3390/pharma4020007. CC BY 4.0.
Tdap — Additional VAERS Data (DARE-SAFE 2025)
The DARE-SAFE paper also reports separate data for the adult/adolescent Tdap formulation:
Passive Surveillance: AE Type Breakdown (Multi-System)
Side-by-side view of U.S. VAERS, Health Canada Canada Vigilance, Japan JADER (PMDA), EU EudraVigilance, and live-scraped international systems via SurVigilance (VigiAccess, Lareb, DAEN, DMA, Medsafe). SurVigilance panels show MedDRA PT mention totals (not individual-case counts). Category assignment uses keyword matching — approximate, not official SOC coding. VAERS files on this site are built from the public VAERS download. FAERS figures use the public quarterly FAERS files. Counts are mentions or reports, not incidence.
VAERS (United States)
Canada Vigilance (Canada)
JADER (PMDA, Japan)
EudraVigilance (EU)
32,489 individual cases · adrreports.eu DAP export (up to 28/06/2026)
Reaction SOC breakdown not included in this workbook export.
Denmark DMA interactive ADR search is currently offline (Danish Medicines Agency IT transition; public overviews frozen at 12 Mar 2024). Live product PT tables cannot be retrieved until DKMA restores the search. See DKMA notice. Denmark continues to report into EU EudraVigilance (panel above).
Medsafe (New Zealand)
VAERS (U.S., 2006–2024): 44,345 symptom mentions (9.07/100k doses). Largest share: Other / Unclassified (34%), Injection-site / Local reaction (25%), General / Systemic (non-local) (10%). Canada Vigilance (CV Online extract): 23,516 reaction mentions in 7,886 unique reports (33.7% serious (2,658 of 7,886 reports)). Largest share: General / Systemic (non-local) (27%), Injection-site / Local reaction (16%), Psychiatric / Neuropsychiatric (15%). JADER (PMDA public CSV extract): 2,059 reaction mentions in 1,232 unique reports (3.9% serious (48 of 1,232 reports)). Largest share: Other / Unclassified (27%), Respiratory (23%), General / Systemic (non-local) (17%). EudraVigilance (EU DAP export): 32,489 individual cases (up to 28/06/2026). Reaction SOC categories were not exported in the local DAP workbooks — case count only. VigiAccess (WHO): 647,774 reaction-term mentions · search: DTP. Largest share: Injection-site / Local reaction (26%), General / Systemic (non-local) (20%), Other / Unclassified (12%). Lareb (Netherlands): 8,831 reaction-term mentions · search: diphtheria tetanus pertussis vaccine. Largest share: General / Systemic (non-local) (27%), Injection-site / Local reaction (21%), Neurological (15%). DAEN (Australia): 64,516 reaction-term mentions · search: pertussis. Largest share: Injection-site / Local reaction (24%), Other / Unclassified (14%), General / Systemic (non-local) (13%). Medsafe (New Zealand): 4,021 reaction-term mentions · search: DTP. Largest share: Gastrointestinal (51%), Other / Unclassified (25%), Cardiac / Cardiovascular (9%). Cross-database note: All systems are passive and unverified; reporting rates are not directly comparable across countries (different populations, reporting incentives, and lack of dose denominators for Canada/Japan/EU). top VAERS: Other / Unclassified; top Canada Vigilance: General / Systemic (non-local); top JADER: Other / Unclassified. SurVigilance note: VigiAccess, Lareb, DAEN, DMA, and Medsafe counts are live-scraped MedDRA PT mention totals (not deduplicated individual cases). Data via SurVigilance (GPL-3.0; pip install SurVigilance). Category assignment uses keyword matching on reported reaction terms — approximate and exploratory. Neither database establishes causality.
Pharmacovigilance Lot Signal Detection — Hypothesis-Generating Only
Multi-system context below. VAERS (U.S.) supports lot-level volume z-scores and seriousness flags by product and lot (2006–2026). Each lot links to a summary with report count, seriousness %, adverse-event pie chart, U.S. state map, and timeline. A signal flag means a statistical threshold was exceeded — not that a lot is unsafe. Full dashboard →
VAERS flags:VOL high report volume (z ≥ 3) ·
BURST clustered in <90 days ·
SER serious reports >50%.
Lot numbers are voluntary/incomplete in VAERS. Location data is U.S. state only (no postal codes in the public extract).
VAERS (United States) — all lots by product
27,631 reports with usable lot across 2,517 lots · 331 flagged
Loading lot tables…
Other Pharmacovigilance Systems
Lot-level analysis is only possible where reporters supply batch/lot numbers in the public extract. Canada Vigilance, JADER (PMDA, Japan), and most other national systems publish product-level spontaneous reports without lot fields.
Canada Vigilance (Health Canada)
7,886 unique reports · 23,516 reaction mentions · 33.7% serious (2,658 of 7,886 reports). Top categories: General / Systemic (non-local) (27%), Injection-site / Local reaction (16%), Psychiatric / Neuropsychiatric (15%).
Canada Vigilance spontaneous reports are unverified temporal associations. The public CV Online data extract does not include lot or batch numbers, so lot-level signal detection is not possible for this system — only product-level reaction patterns are shown here. No Canadian dose denominators are available. Extract 2026-03-31.
1,232 unique reports · 2,059 reaction mentions · 3.9% serious (48 of 1,232 reports). Top categories: Other / Unclassified (27%), Respiratory (23%), General / Systemic (non-local) (17%).
JADER (Japanese Adverse Drug Event Report database) spontaneous reports are unverified temporal associations; PMDA has not assessed causality per case. The public CSV extract does not include lot or batch numbers, so lot-level signal detection is not possible — only product-level reaction patterns are shown here. Reaction terms in source data use MedDRA/J Preferred Terms. JADER CSV extract pmdacasereport202606 (2026-06). JADER reference (PDF)
32,489 individual cases (up to 28/06/2026) · DIPHTHERIA, TETANUS AND PERTUSSIS (ACELLULAR, COMPONENT) VACCINE (ADSORBED). Reaction SOC breakdown not included in this DAP export.
EudraVigilance spontaneous reports are unverified temporal associations. The local EudraVigilance DAP workbooks provide individual-case counts from adrreports.eu; exported Reaction SOC filters were not set, so reaction-category charts are unavailable from this extract. Lot/batch numbers are not in public line listings.
Active Pharmacovigilance (Defined-Population Surveillance)
Curated findings for DTaP / Tdap from active systems (not VAERS). Page inventory last reviewed: 2026-07-10.
ⓘ Active vs. passive — why this pane is separate
The VAERS / multi-system charts above are passive surveillance: spontaneous, unverified reports without a fixed denominator.
Active surveillance starts from a defined, enumerated population (EHR/claims or structured post-vaccination surveys), applies pre-specified statistical tests, and asks whether an outcome occurs
more often than expected in a risk window versus a comparison window or group.
These are not two flavors of the same evidence — active findings are the harder tier that can confirm, refute, or leave under investigation a signal first hinted in passive data.
Do not add VAERS report counts to active incidence rates.
○ No signal detected◐ Signal under investigation◑ Investigated — not confirmed● Signal confirmed (true association)– Not currently under active surveillance
Acellular pertussis vaccines were adopted largely to reduce reactogenicity versus whole-cell products. VSD and related systems continue to monitor DTaP/Tdap; no new confirmed rare serious risk on the order of rotavirus intussusception or COVID myocarditis has redefined routine use. Maternal Tdap safety has been a focus of dedicated studies.
Population
Infants/children (DTaP) and adolescents/adults (Tdap) at VSD sites
Risk interval
Study-specific
Comparison
Control intervals
Evaluation period
Decades of post-licensure active work; acellular era since 1990s–2000s
Method
Observational studies and RCA for combination/schedule questions
Update cadence: Tier 1: check AusVaxSafety monthly when public pages update. Tier 2/3: quarterly review around ACIP meetings and PubMed/MMWR; set lastReviewed per record.
Source tiers: Tier 1 = public near-real-time dashboards (e.g. AusVaxSafety);
Tier 2 = VSD / Sentinel / PRAC-type findings released via ACIP slides, MMWR, or papers (no public VSD raw dashboard);
Tier 3 = regulator label/safety communications.
Detecting a signal and later classifying it as not confirmed is normal system behavior — not an anomaly to hide or amplify.
4. Documented Adverse Events — Evidence of Association
Rank-aggregated VAERS signal detection (rankv)
The table below lists vaccine–event pairs that were detected as disproportionality signals by all four base methods used in rankv (GPS, PRR, ROR, BCPNN) on multi-decade VAERS data, then ordered by rank aggregation (Borda average rank; related to the Spearman/GA top-list approach in the rankv paper).
Data: ~30 years of public VAERS (rankv processed tables).
Origin: precisionFDA “Gaining New Insights by Detecting Adverse Event Anomalies” challenge solution.
Caveat: Disproportionality signals are statistical associations in spontaneous reports. They do not establish causality, incidence, or product defect. Many top pairs reflect administration/product-use coding rather than clinical injury.
Injection site reactions (pain, swelling, erythema): Very common. Extensive limb swelling (2–6%) with booster doses—self-limited. Strong
Fever (infants): ~15–30% with DTaP; lower than DTwP (40–60%). Strong
Febrile seizures: Small increased risk in the 0–1 day post-vaccination window (~1 per 15,000–25,000 doses), particularly with concomitant vaccines. Strong
Crying/inconsolability (infants): Common (10–30%). Self-limited (1–2 days). Strong
Hypotonic-hyporesponsive episode (HHE): Rare (~1–2 per 100,000 DTaP doses). Self-limited; does not cause long-term sequelae. Strong
Anaphylaxis: ~1–3 per million doses. Attributable to vaccine components. Strong
Shoulder Injury Related to Vaccine Administration (SIRVA): Bursitis/tendonitis from improper injection technique (too high on the deltoid). Not antigen-specific; procedure-related. Strong
▶ Moderate or Preliminary Evidence
Guillain-Barré Syndrome (GBS): IOM deemed evidence inadequate. Some tetanus toxoid studies suggest a possible very small increase, not consistently replicated. VSD rapid cycle analysis has not found a significant signal. Limited
▶ Published Evidence Does Not Support a Causal Association
SIDS: Multiple large studies; no association. IOM (2003) rejected causality. No Association
Autism: No association. IOM (2012) rejected causality. No Association
Encephalopathy: Thought to be associated with DTwP in rare cases; large studies of DTaP have not found an association. IOM (2012) favored rejection for DTaP and encephalopathy. No Association
Adverse pregnancy outcomes (Tdap): Multiple VSD and registry studies; no increased risk. No Association
5. Disease Prevention Benefits
Pre-Vaccine vs. Post-Vaccine Era (United States)
Metric
Pre-Vaccine Era
Post-Vaccine Era
Diphtheria cases (annual)
~200,000 (1920s); ~15,000 deaths/year
<5 cases/year since 2000; last U.S. death 2003
Tetanus cases (annual)
~500–600 (1940s)
~30/year; nearly all unvaccinated
Pertussis cases (annual)
~200,000 (pre-1940s)
~10,000–50,000 (post-DTaP era, with cyclical peaks); resurgence in the 2010s attributed to waning DTaP immunity
Pertussis infant mortality
~5,000–7,000 deaths/year
~10–20 deaths/year (primarily infants <3 months too young for vaccination; maternal Tdap has reduced this further)
Diphtheria and tetanus: Near-elimination in the U.S., demonstrating high and durable vaccine effectiveness.
Pertussis resurgence: The switch from DTwP to DTaP reduced reactogenicity but may have reduced durability of protection. A 2012 Washington State epidemic (~5,000 cases) and a 2014 California epidemic (~11,000 cases) occurred in highly vaccinated populations, documenting waning DTaP immunity. Adolescent Tdap boosters and maternal Tdap are strategies to address this.
Maternal Tdap effectiveness: Maternal Tdap during pregnancy has been shown to prevent ~78–91% of pertussis cases in infants <2 months of age (the highest-risk population), according to multiple observational studies (Amirthalingam et al., UK, 2014; Skoff et al., U.S., 2017).
Disease Burden Over Time
Reported U.S. disease burden by year. The dashed vertical line marks vaccine introduction. Hover or tap data points for values; use arrow keys when a chart has focus.
ⓘ About these charts: These are accessible SVG line charts with keyboard navigation, hover tooltips, and an underlying data table (expand below). The dashed vertical line marks the year of vaccine introduction. Reported cases undercount true incidence; case definitions, reporting practices, and diagnostic methods have changed over time. See Section 5 for additional context and pre-vs-post era comparisons.
7. Evidence Summary
Overall Assessment
DTP vaccines have been in use for >70 years. The safety profile of the current DTaP/Tdap products is well-characterized for common adverse events and extensively studied for rare outcomes. The primary evidence gap is the durability of pertussis protection, which post-licensure data have shown to be shorter than initially expected. Injection site and fever-related reactions are common but self-limited. Serious adverse events (anaphylaxis, febrile seizures, HHE) are rare and well-characterized.
Domain
Evidence Grade
Key Finding
Diphtheria/tetanus effectiveness
Strong
Near-elimination; durable immunity
Pertussis effectiveness (initial)
Strong
~80–85% effective first 1–2 years
Pertussis durability (waning)
Strong
Significant waning by 3–5 years post-vaccination
Maternal Tdap for infant protection
Strong
~78–91% effective in preventing infant pertussis
Febrile seizures
Strong
~1 per 15,000–25,000 doses; well-characterized
GBS
Limited
Inadequate data; no consistent signal
SIDS
No Association
Multiple large studies; no association
8. International Surveillance & Global Data
Quick links to public pharmacovigilance databases and trial registries relevant to DTaP/Tdap Vaccine. Reporting counts do not establish causality.
Note: Spontaneous reports are unverified observations. Compare with epidemiological studies in Sections 3–6 before drawing conclusions.
9. Curated Adverse Event Literature
Curated peer-reviewed literature linking specific adverse events to DTaP/Tdap Vaccine. Each entry is a case report, case series, or related safety publication identified via PubMed. Expand Search PubMed for additional literature below to run custom queries.
Disclaimer: Published reports describe observations and associations; they do not establish population incidence or causality.
Common questions
How long do DTaP/Tdap vaccine side effects last?
Most reported DTaP/Tdap vaccine reactions are short-lived: injection-site soreness, tiredness, and low-grade fever that typically begin within a day or two and resolve within a few days. Longer-lasting or more serious events are rarer and are the ones tracked in the post-licensure surveillance and documented adverse-event sections of this page, with report counts that are not incidence rates. Anything severe or persisting beyond a week warrants medical review.
Is the DTaP/Tdap vaccine given to adults, and are side effects different in adults?
Whether the DTaP/Tdap vaccine is recommended for adults depends on the vaccine and the person's risk factors; the schedule and product sections above describe the licensed indications and age groups. Reporting patterns in adults can differ from children, so this page's VAERS and international database breakdowns should be read with the reporting population in mind. Check the current CDC/ACIP adult schedule and the product's prescribing information for adult dosing.
10. Key References
IOM. Adverse Effects of Vaccines: Evidence and Causality. National Academies Press; 2012. nationalacademies.org
CDC. Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book) — Diphtheria, Tetanus, Pertussis chapters. cdc.gov/pinkbook
Kharbanda EO, et al. Safety of Tdap vaccine in pregnant women. JAMA. 2014;312(18):1897–1904. DOI: 10.1001/jama.2014.14825
Skoff TH, et al. Impact of the US maternal Tdap vaccination program. Clin Infect Dis. 2017;65(12):1977–1983.
Amirthalingam G, et al. Effectiveness of maternal pertussis vaccination in England. The Lancet. 2014;384(9953):1521–1528.